$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000155905316000074 Filed on August 02, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$286.0K	$333.0K	$278.0K
YoY Change	-33.33%	19.78%	-98.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.14M	$8.130M	$5.520M
YoY Change	173.1%	47.28%	11.74%
% of Gross Profit
Research & Development	$26.84M	$32.36M	$12.79M
YoY Change	56.17%	152.98%	48.47%
% of Gross Profit
Depreciation & Amortization	$800.0K	$400.0K	$200.0K
YoY Change	300.0%	100.0%	0.0%
% of Gross Profit
Operating Expenses	$42.97M	$40.49M	$18.31M
YoY Change	86.12%	121.12%	35.13%
Operating Profit	-$42.69M	-$40.16M	-$18.04M
YoY Change	88.38%	122.68%	-1249.46%
Interest Expense	$140.0K	-$10.00K	$40.00K
YoY Change	180.0%	-125.0%	100.0%
% of Operating Profit
Other Income/Expense, Net	-$130.0K	-$96.00K	-$47.00K
YoY Change	68.83%	104.26%	-376.47%
Pretax Income	-$42.82M	-$40.26M	-$18.08M
YoY Change	88.31%	122.63%	-1240.1%
Income Tax	$421.0K	$189.0K	$195.0K
% Of Pretax Income
Net Earnings	-$43.24M	-$40.45M	-$18.28M
YoY Change	88.19%	121.29%	-1516.82%
Net Earnings / Revenue	-15118.53%	-12145.65%	-6574.46%
Basic Earnings Per Share	-$1.26	-$1.18	-$0.59
Diluted Earnings Per Share	-$1.26	-$1.18	-$0.59
COMMON SHARES
Basic Shares Outstanding	34.40M shares	34.35M shares	30.79M shares
Diluted Shares Outstanding			30.79M shares

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$408.6M	$442.9M	$402.4M
YoY Change	5.36%	10.06%	32.41%
Cash & Equivalents	$408.6M	$442.9M	$402.4M
Short-Term Investments
Other Short-Term Assets	$6.700M	$7.300M	$2.900M
YoY Change	34.0%	151.72%	81.25%
Inventory
Prepaid Expenses
Receivables	$409.0K	$364.0K	$961.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$415.6M	$450.6M	$406.2M
YoY Change	5.61%	10.93%	32.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$51.74M	$41.85M	$2.816M
YoY Change	1665.8%	1386.22%	-15.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.162M	$2.363M	$2.100M
YoY Change	30785.71%	12.52%	7400.0%
Total Long-Term Assets	$63.94M	$51.96M	$4.964M
YoY Change	1094.32%	946.82%	6.39%
TOTAL ASSETS
Total Short-Term Assets	$415.6M	$450.6M	$406.2M
Total Long-Term Assets	$63.94M	$51.96M	$4.964M
Total Assets	$479.6M	$502.6M	$411.2M
YoY Change	20.22%	22.23%	31.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.54M	$11.59M	$2.865M
YoY Change	159.73%	304.61%	93.19%
Accrued Expenses	$22.60M	$19.70M	$9.100M
YoY Change	73.85%	116.48%	16.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$36.91M	$33.46M	$13.46M
YoY Change	98.88%	148.63%	18.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$126.0K	$126.0K
YoY Change	-100.0%	0.0%	-93.7%
Total Long-Term Liabilities	$41.57M	$38.24M	$2.488M
YoY Change	1618.64%	1437.02%	27.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.91M	$33.46M	$13.46M
Total Long-Term Liabilities	$41.57M	$38.24M	$2.488M
Total Liabilities	$78.48M	$71.70M	$15.94M
YoY Change	274.13%	349.68%	20.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$240.3M	-$197.1M	-$81.97M
YoY Change	128.98%	140.42%	269.25%
Common Stock	$344.0K	$343.0K	$314.0K
YoY Change	9.21%	9.24%	17.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.1M	$430.9M	$395.2M
YoY Change
Total Liabilities & Shareholders Equity	$479.6M	$502.6M	$411.2M
YoY Change	20.22%	22.23%	31.92%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$43.24M	-$40.45M	-$18.28M
YoY Change	88.19%	121.29%	-1516.82%
Depreciation, Depletion And Amortization	$800.0K	$400.0K	$200.0K
YoY Change	300.0%	100.0%	0.0%
Cash From Operating Activities	-$29.76M	-$27.53M	-$11.14M
YoY Change	75.99%	147.13%	-279.1%
INVESTING ACTIVITIES
Capital Expenditures	-$8.560M	-$700.0K	-$40.00K
YoY Change	2493.94%	1650.0%	-87.5%
Acquisitions
YoY Change
Other Investing Activities	$4.060M	-$4.060M
YoY Change
Cash From Investing Activities	-$4.500M	-$4.760M	-$40.00K
YoY Change	1263.64%	11800.0%	-87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.950M	980.0K	133.7M
YoY Change	49.06%	-99.27%	29.93%
NET CHANGE
Cash From Operating Activities	-29.76M	-27.53M	-11.14M
Cash From Investing Activities	-4.500M	-4.760M	-40.00K
Cash From Financing Activities	3.950M	980.0K	133.7M
Net Change In Cash	-30.31M	-31.31M	122.5M
YoY Change	107.75%	-125.55%	12.61%
FREE CASH FLOW
Cash From Operating Activities	-$29.76M	-$27.53M	-$11.14M
Capital Expenditures	-$8.560M	-$700.0K	-$40.00K
Free Cash Flow	-$21.20M	-$26.83M	-$11.10M
YoY Change	27.86%	141.71%	-269.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34395876	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
	dei	Trading Symbol TradingSymbol	PRTA
	prta	Accrued Offering Costs AccruedOfferingCosts	41000	USD
	prta	Accrued Offering Costs AccruedOfferingCosts	0	USD
CY2015Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	12794000	USD
CY2016Q2	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	16650000	USD
CY2015Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	0	USD
CY2016Q2	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	35933000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	0	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	326000	USD
CY2015Q2	prta	Collaboration Revenue CollaborationRevenue	278000	USD
	prta	Collaboration Revenue CollaborationRevenue	871000	USD
	prta	Collaboration Revenue CollaborationRevenue	598000	USD
CY2016Q2	prta	Collaboration Revenue CollaborationRevenue	333000	USD
CY2015Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q2	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q2	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2015Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2016Q2	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2015Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2016Q2	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0.0	shares
CY2016Q2	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2015Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q2	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q2	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2015Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2016Q2	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2016Q2	prta	Future Minimum Sublease Rentals FutureMinimumSubleaseRentals	-577000	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Thereafter FutureMinimumSubleaseRentalsThereafter	0	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Year Five FutureMinimumSubleaseRentalsYearFive	0	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Year Four FutureMinimumSubleaseRentalsYearFour	0	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Year One FutureMinimumSubleaseRentalsYearOne	-261000	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Year Three FutureMinimumSubleaseRentalsYearThree	0	USD
CY2016Q2	prta	Future Minimum Sublease Rentals Year Two FutureMinimumSubleaseRentalsYearTwo	-316000	USD
CY2015Q1	prta	Gain Losson Sublease GainLossonSublease	-400000	USD
	prta	Gain Losson Sublease Noncash Portion GainLossonSubleaseNoncashPortion	-261000	USD
	prta	Gain Losson Sublease Noncash Portion GainLossonSubleaseNoncashPortion	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	325000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	0	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	11000	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	0	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	37571000	USD
	prta	Numberof Votes NumberofVotes	1	vote
	prta	Operating Leases Annual Rent Payment OperatingLeasesAnnualRentPayment	2100000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	800000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Due For Remainderof Year PurchaseandContractualObligationDueForRemainderofYear	17120000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	122000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	150000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	206000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	173000	USD
CY2016Q2	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	18571000	USD
CY2015Q1	prta	Sublease Leases Optional Extension Term SubleaseLeasesOptionalExtensionTerm	P1Y
CY2015Q1	prta	Sublease Leases Term SubleaseLeasesTerm	P3Y
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4519000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11592000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	509000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	364000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2016Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	325000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	615000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5343000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6014000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	489455000	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	627591000	USD
CY2016Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	50400	sqft
CY2015Q4	us-gaap	Assets Assets	385236000	USD
CY2016Q2	us-gaap	Assets Assets	502562000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	377403000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	450598000	USD
CY2015Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	7833000	USD
CY2016Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	51964000	USD
CY2015Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	167000	USD
CY2016Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	225000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293579000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	402389000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	370586000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	442948000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	108810000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	72362000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31744102	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34381501	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34381501	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31744102	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34381501	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	317000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	343000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	USD
CY2016Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	38554000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-426000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-854000	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	284000	USD
CY2016Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	320000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2127000	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2084000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	2850000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	3693000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	700000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	388000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	679000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3774000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3035000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	989000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	300000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	989000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	300000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5522000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10571000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8134000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15316000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18082000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33018000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-40256000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-67596000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	195000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	461000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	370000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	442000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	877000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1908000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9349000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-768000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-145000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-30000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1560000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2331000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	4056000	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	40000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	66000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-10000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	267000	USD
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-11-30
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2828000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2764000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	24567000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	71697000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	385236000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	502562000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22216000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	33456000	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2351000	USD
CY2016Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	38241000	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6210000	USD
CY2016Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6323000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134738000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	130043000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4998000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25860000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52683000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-18277000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33479000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-40445000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-67966000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	15000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	16000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-47000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	46000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	18313000	USD
	us-gaap	Operating Expenses OperatingExpenses	33935000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	40493000	USD
	us-gaap	Operating Expenses OperatingExpenses	68168000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18035000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33064000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-40160000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-67570000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11432000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1090000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2287000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2410000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2326000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2246000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1073000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1121000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2363000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4903000	USD
CY2016Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5214000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	126000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	126000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-87000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-86000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-293000	USD
CY2015Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	520000	USD
CY2016Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1244000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	68000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	942000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6308000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7286000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131481000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128777000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2268000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9205000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47866000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3862000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41852000	USD
CY2016Q2	us-gaap	Purchase Obligation PurchaseObligation	17181000	USD
CY2016Q2	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2016Q2	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	32000	USD
CY2016Q2	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	30000	USD
CY2016Q2	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	86000	USD
CY2016Q2	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	53000	USD
CY2016Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	16980000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12791000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23364000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32359000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52852000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129103000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197069000	USD
CY2015Q2	us-gaap	Revenues Revenues	278000	USD
	us-gaap	Revenues Revenues	871000	USD
CY2016Q2	us-gaap	Revenues Revenues	333000	USD
	us-gaap	Revenues Revenues	598000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2416000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4119000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4546000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8270000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1850000	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	360669000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	430865000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30792000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29106000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34358000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34192000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2015 are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. Credit risk exposure is up to the extent of amounts recorded on the Company's Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> were held in Ireland. </font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, storage, testing or distribution of preclinical or clinical supplies of any of its drug candidates. The Company instead contracted with and relies on third-parties to manufacture, store, test and distribute all preclinical development and clinical supplies of its drug candidates, and the Company plans to continue to do so for the foreseeable future. Currently, the Company has a single source of preclinical or clinical supplies for each of its drug candidates. A delay or inability to obtain such supply could have an adverse effect on the Company's business, financial condition and results of operations.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-16-000074-index-headers.html	Edgar Link	pending
0001559053-16-000074-index.html	Edgar Link	pending
0001559053-16-000074.txt	Edgar Link	pending
0001559053-16-000074-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prta-20160630.xml	Edgar Link	completed
prta-20160630.xsd	Edgar Link	pending
prta-20160630_cal.xml	Edgar Link	unprocessable
prta-20160630_def.xml	Edgar Link	unprocessable
prta-20160630_lab.xml	Edgar Link	unprocessable
prta-20160630_pre.xml	Edgar Link	unprocessable
prta2016q210-q.htm	Edgar Link	pending
prta2016q210-qxex311.htm	Edgar Link	pending
prta2016q210-qxex312.htm	Edgar Link	pending
prta2016q210-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2016 Q3 Form 10-Q Financial Statement

#000155905316000074 Filed on August 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2016 Q3 Form 10-Q Financial Statement

#000155905316000074 Filed on August 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta